Purification, crystallization and preliminary X‐ray analysis of Enterococcus casseliflavus aminoglycoside‐2′′‐phosphotransferase‐IVa

The deactivation of aminoglycoside antibiotics by chemical modification is one of the major sources of bacterial resistance to this family of therapeutic compounds, which includes the clinically relevant drugs streptomycin, kanamycin and gentamicin. The aminoglycoside phosphotransferases (APHs) form one such family of enzymes responsible for this resistance. The gene encoding one of these enzymes, aminoglycoside‐2′′‐phosphotransferase‐IVa [APH(2′′)‐IVa] from  Enterococcus casseliflavus , has been cloned and the protein (comprising 306 amino‐acid residues) has been expressed in Escherichia coli and purified. The enzyme was crystallized in three substrate‐free forms. Two of the crystal forms belonged to the orthorhombic space group P 2 1 2 1 2 1 with similar unit‐cell parameters, although one of the crystal forms had a unit‐cell volume that was approximately 13% smaller than the other and a very low solvent content of around 38%. The third crystal form belonged to the monoclinic space group P 2 1 and preliminary X‐ray diffraction analysis was consistent with the presence of two molecules in the asymmetric unit. The orthorhombic crystal forms of apo APH(2′′)‐IVa both diffracted to 2.2 Å resolution and the monoclinic crystal form diffracted to 2.4 Å resolution; synchrotron diffraction data were collected from these crystals at SSRL (Stanford, California, USA). Structure determination by molecular replacement using the structure of the related enzyme APH(2′′)‐IIa is proceeding.